Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines

BACKGROUND: Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC. The majority of advanced HCC patients are resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Haga, Yuki, Kanda, Tatsuo, Nakamura, Masato, Nakamoto, Shingo, Sasaki, Reina, Takahashi, Koji, Wu, Shuang, Yokosuka, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360329/
https://www.ncbi.nlm.nih.gov/pubmed/28323861
http://dx.doi.org/10.1371/journal.pone.0174153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360329/
https://www.ncbi.nlm.nih.gov/pubmed/28323861
http://dx.doi.org/10.1371/journal.pone.0174153

Ejemplares similares